Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Arcadia Biosciences (RKDA) EBIAT (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EBIAT readings, the most recent being -$1.3 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 67.13% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.3 million, a 64.6% increase, with the full-year FY2025 number at -$2.3 million, up 66.77% from a year prior.
  • EBIAT hit -$1.3 million in Q4 2025 for Arcadia Biosciences, down from $856000.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $144.0 million in Q2 2021 to a low of -$9.4 million in Q1 2023.
  • Median EBIAT over the past 5 years was -$2.6 million (2021), compared with a mean of $4.9 million.
  • Biggest five-year swings in EBIAT: soared 1555.57% in 2021 and later plummeted 520.17% in 2025.
  • Arcadia Biosciences' EBIAT stood at -$7.5 million in 2021, then soared by 40.43% to -$4.5 million in 2022, then surged by 35.83% to -$2.9 million in 2023, then crashed by 41.75% to -$4.1 million in 2024, then skyrocketed by 67.13% to -$1.3 million in 2025.
  • The last three reported values for EBIAT were -$1.3 million (Q4 2025), $856000.0 (Q3 2025), and -$4.5 million (Q2 2025) per Business Quant data.